Dr Arthur Pratt
Intermediate Clinical Fellow, Honorary Consulatant Rheumatologist
- Email: firstname.lastname@example.org
- Telephone: +44 (0) 191 208 5462
Dr. Arthur G Pratt
BSc, MBChB, MRCP, PhD
Intermediate Clinical Fellow,
Honorary Consultant Rheumatologist.
Arthur completed his medical training at Leeds Medical School in 2001, with an intercalated BSc degree in Molecular Medicine. After house jobs in Yorkshire and Nottingham he was admitted to the Royal College of Physicians in 2004. Having moved to the Northeast for his specialist Rheumatology training, he was awarded an Arthritis Research UK Research Training Fellowship in 2007. Whilst helping to develop the Newcastle Early Arthritis Clinic, he carried out research into biomarkers for diagnosing seronegative rheumatoid arthritis – work which formed the basis of his PhD thesis. Following a spell as NHIR Clinical Lecturer in Rheumatology, he was recently appointed as an Intermediate Clinical Fellow at Newcastle University. His time is divided between NHS work as an Honorary Consultant Rheumatologist (running the early arthritis service at The Freeman Hospital), clinical trial work, and research (including PhD student supervision) within the Institute of Cellular Medicine.
I am interested in how an improved understanding of the aetiopathogenesis of early rheumatoid arthritis (RA) might improve our ability to diagnose and treat patients with the disease. My research seeks to identify molecular biomarkers that begin to stratify this highly heterogeneous condition into subgroups of clinical significance.
Rheumatoid arthritis is a chronic and highly heterogeneous disease of immune dysregulation characterised by painful and destructive inflammation of synovial joints. Despite a wealth of existing and emerging therapies there is no cure for the condition, which remains a cause of disability, reduced quality of life and increased mortality. An overarching aim in our laboratory is to develop biomarkers that stratify patients according to pathobiology during the earliest clinical stage of RA, potentially enabling more rational therapeutic targeting.
We have developed a well characterised early arthritis inception cohort which has provided a rich resource for observational studies. Genetic investigations increasingly emphasise an orchestrating role for CD4+ lymphocytes in RA pathogenesis, and our work to date has focused on this cell type: our recent expression quantitative trait locus (eQTL) analysis of CD4+ lymphocytes in untreated arthritis patients refined the candidate causal gene landscape of RA. The transcriptome of these cells also points to the importance of interleukin-6 mediated STAT3 signalling as an early event in a diagnostically challenging RA sub-group, and we have validated this finding using flow cytometry, with potential implications for the clinic. Such observations inform our in vitro study of mechanisms of CD4+ lymphocyte dysregulation underpinning RA.
- Orr C, Sousa E, Boyle DL, Buch MH, Buckley CD, Canete JD, Catrina AI, Choy EHS, Emery P, Fearon U, Filer A, Gerlag D, Humby F, Isaacs JD, Just SoA, Lauwerys BR, Le Goff B, Manzo A, McGarry T, McInnes IB, Najm A, Pitzalis C, Pratt A, Smith M, Tak PP, Thurlings R, Fonseca JE, Veale DJ. Synovial tissue research: A state-of-the-art review. Nature Reviews Rheumatology 2017, 13(8), 463-475.
- Pratt AG, Anderson AE, Carmody RJ, Isaacs JD. Bcl-3 in CD4+ T Cell–Mediated Rheumatoid Arthritis Pathogenesis: Comment on the Article by Meguro et al. Arthritis and Rheumatology 2016, 68(3), 770-771.
- McGovern A, Schoenfelder S, Martin P, Massey J, Duffus K, Plant D, Yarwood A, Pratt AG, Anderson AE, Isaacs JD, Diboll J, Thalayasingam N, Ospelt C, Barton A, Worthington J, Fraser P, Eyre S, Orozco G. Capture Hi-C identifies a novel causal gene, IL20RA, in the pan-autoimmune genetic susceptibility region 6q23. Genome Biology 2016, 17, 212.
- Pratt AG, Lendrem D, Hargreaves B, Aslam O, Galloway JB, Isaacs JD. Components of treatment delay in rheumatoid arthritis differ according to autoantibody status: validation of a single-centre observation using national audit data. Rheumatology 2016, 55(10), 1843-1848.
- Hanson H, Isaacs JD, Kay LJ, Lendrem DW, O'Brien N, Pratt AG, Rapley T. Experiences of staff and patients in relation to clinical research recruitment and involvement: a qualitative study. In: Rheumatology. 2016, Glasgow: Oxford University Press.
- Pratt AG, Massey J, Anderson AE, Nair N, Diboll J, Skelton A, Lendrem DW, Reynard LN, Cordell HJ, Eyre S, Barton A, Isaacs JD. Identification of novel expression quantitative trait loci in CD4+ T cells of untreated early arthritis patients. In: 36th European Workshop for Rheumatology Research. 2016, York: BMJ Group.
- Anderson AE, Pratt AG, Sedhom MA, Doran JP, Routledge C, Hargreaves B, Brown PB, LeCao KA, Isaacs JD, Thomas R. IL-6-driven STAT signalling in circulating CD4+ lymphocytes is a marker for early anti-citrullinated peptide antibody-negative rheumatoid arthritis. Annals of the Rheumatic Diseases 2016, 75, 466-473.
- Brown PM, Pratt AG, Isaacs JD. Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nature Reviews Rheumatology 2016, 12(12), 731-742.
- Pollock J, Raza K, Pratt AG, Hanson H, Siebert S, Filer A, Isaacs JD, Buckley CD, Mcinnes IB, Falahee M. Patient and researcher perspectives on facilitating patient and public involvement in rheumatology research. Musculoskeletal Care 2016, (ePub ahead of Print).
- Baker KF, Pratt AG, Thompson B, Isaacs JD. Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers. Annals of the Rheumatic Diseases 2016, (ePub ahead of Print).
- Reynolds G, Gibbon JR, Pratt AG, Coady D, Raftery G, Lorenzi AR, Gray A, Filer A, Buckley CD, Haniffa MA, Isaacs JD, Hilkens CM. Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis. Annals of the Rheumatic Diseases 2016, 75(5), 899-907.
- Anderson AE, Swan DJ, Wong OY, Buck M, Eltherington O, Harry RA, Patterson AM, Pratt AG, Reynolds G, Doran JP, Kirby JA, Isaacs JD, Hilkens CM. Tolerogenic dendritic cells generated with dexamethasone and vitamin D3 regulate rheumatoid arthritis CD4+ T-cells partly via TGF-β1. Clinical & Experimental Immunology 2016, (ePub ahead of Print).
- Baker KF, Thompson B, Lendrem DW, Pratt AG, Isaacs JD. Ultrasound measures of synovitis are independent of clinical parameters in the setting of rheumatoid arthritis remission: a cross-sectional analysis. In: 2016 Annual European Congress of Rheumatology. 2016, London, UK: BMJ Publishing Group.
- Pratt AG, Hargreaves B, Lendrem DW, Aslam O, Isaacs JD. Components of treatment delay in rheumatoid arthritis differ according to autoantibody status. In: 2015 ACR/ARHP Annual Meeting. 2015, San Francisco, CA, USA: John Wiley & Sons, Inc.
- Pratt AG, Isaacs JD. Genotyping in rheumatoid arthritis: a game changer in clinical management?. Expert Review of Clinical Immunology 2015, 11(3), 303-305.
- Cooles FAH, Pratt AG, Lendrem DW, Ng WF, Aspray TJ, Isaacs JD. Retrospective analysis of the role of serum vitamin D in early rheumatic disease. Rheumatology 2015, 54(2), 374-375.
- Pratt AG, Anderson AE, Lendrem DW, Skelton A, Massey J, Nair N, Diboll J, Hargreaves B, Brown PM, Barton A, Isaacs JD. STAT3-regulated gene expression in circulating CD4+ T cells discriminates RA patients independently of clinical parameters in early arthritis: a validation study. In: 2015 ACR/ARHP Annual Meeting. 2015, San Francisco, CA.
- Pratt AG, Anderson AE, Nair N, Massey J, Diboll J, Skelton A, Hargreaves B, Routledge C, Lendrem D, Brown P, Barton A, Isaacs JD. The Importance of IL-6-STAT3 Mediated Activation of Circulating CD4+ T Cells in the Pathogenesis of Early Seronegative Rheumatoid Arthritis: A Validation Study. In: Rheumatology 2015. 2015, Manchester, UK: Oxford University Press.
- Anderson A, Routledge C, Isaacs J, Pratt A. Investigation of interleukin-6-driven STAT3 signalling in circulating lymphocytes of patients with early rheumatoid arthritis as a route to biomarker discovery. In: Spring Meeting for Clinician Scientists in Training. 2014, London, UK: Elsevier.
- Pratt AG, Isaacs JD. Seronegative rheumatoid arthritis: Pathogenetic and therapeutic aspects. Best Practice & Research Clinical Rheumatology 2014, 28(4), 651-659.
- Pratt AG, Brown PM, Cockell SJ, Wilson G, Isaacs JD. A CD4+T-Cell Gene Expression Signature Predicts Drug Survival on Methotrexate Monotherapy in Early Rheumatoid Arthritis. In: 33rd European Workshop for Rheumatology Research. 2013, Prague, Czech Republic: BMJ Publishing Group.
- Pratt AG, Lorenzi AR, Wilson G, Platt PN, Isaacs JD. Predicting persistent inflammatory arthritis amongst early arthritis clinic patients in the UK: is musculoskeletal ultrasound required?. Arthritis Research & Therapy 2013, 15(5), R118.
- Cooles FAH, Pratt AG, Ng WF, Aspray TJ, Isaacs JD. The Effect Of Vitamin D On Early Rheumatoid Arthritis: A Retrospective Cohort Analysis. In: ACR/ARHP Annual Meeting 2013. 2013, San Diego, CA, USA: Wiley-Blackwell.
- Pratt AG, Swan DC, Richardson S, Wilson G, Hilkens C, Young DA, Isaacs JD. A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly anti-citrullinated peptide antibody-negative disease. Annals of the Rheumatic Diseases 2012, 71(8), 1374-1381.
- Pratt AG, Brown PM, Cockell SJ, Wilson G, Isaacs JD. A CD4+T-Cell Gene Expression Signature Predicts Drug Survival On Methotrexate Monotherapy in Early Rheumatoid Arthritis. In: Annual Scientific Meeting of the American College of Rheumatology (ACR). 2012, Washington, DC, USA: John Wiley & Sons, Inc.
- Anderson AE, Lorenzi AR, Pratt A, Wooldridge T, Diboll J, Hilkens CM, Isaacs JD. Immunity 12 years after alemtuzumab in RA: CD5+ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses. Rheumatology 2012, 51(8), 1397-1406.
- Burmester GR, Pratt AG, Scherer HU, van Laar JM. Rheumatoid arthritis: Pathogenesis and clinical aspects. In: Bijlsma, H, ed. EULAR Textbook on Rheumatic Diseases. London: BMJ Publications, 2012, pp.206-231.
- Cooles FAH, Pratt AG, Wilson G, Isaacs JD, Ng WF. Prevalence and diagnostic outcome relating to vitamin D deficiency in new patients presenting to an early arthritis clinic over 12 months. Clinical Rheumatology 2011, 30(8), 1137-1138.
- Pratt AG, Charles PJ, Chowdhury M, Wilson G, Venables PJ, Isaacs JD. Serotyping for an extended anti-citrullinated peptide autoantibody panel does not add value to CCP2 testing for diagnosing RA in an early undifferentiated arthritis cohort. Annals of the Rheumatic Diseases 2011, 70(11), 2056-2058.
- Tudhope SJ, von Delwig A, Falconer J, Pratt A, Woolridge T, Wilson G, Isaacs JD, Ng WF. Profound invariant natural killer T-cell deficiency in inflammatory arthritis. Annals of the Rheumatic Diseases 2010, 69(10), 1873-1879.
- Pratt AG, Isaacs JD, Mattey DL. Current concepts in the pathogenesis of early rheumatoid arthritis. Best Practice & Research: Clinical Rheumatology 2009, 23(1), 37-48.
- Pratt AG, Isaacs JD, Wilson G. The clinical utility of a rule for predicting rheumatoid arthritis in patients with early undifferentiated arthritis: comment on the article by van der Helm-van Mil et al. Arthritis & Rheumatism 2009, 60(3), 905.
- Lorenzi AR, Patterson AM, Pratt A, Jefferson M, Chapman CE, Ponchel F, Isaacs JD. Determination of thymic function directly from peripheral blood: a validated modification to an established method. Journal of Immunological Methods 2008, 339(2), 185-94.
- Pratt A, Nicholl K, Kay L. Comment on: Use of the QuantiFERON-TB® Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-α agents: The Newcastle (UK) experience: Reply . Rheumatology 2007, 46(12), 1864-1865.
- Marshall NJ, Pratt A, Kay LJ. Pamidronate infusions for Ankylosing Spondylitis give significant benefit to only a minority of patients. In: Rheumatology: Annual Meeting of the British Society of Rheumatology. 2007, Birmingham, UK: Oxford University Press.
- Pratt A, Nicholl K, Kay L. Use of the QuantiFERON TB Gold test as part of a screening programme in patients with RA under consideration for treatment with anti-TNF-α agents: The Newcastle (UK) experience. Rheumatology 2007, 46(6), 1035-1036.